What is the proper way to take eltrombopag tablets, including dosing and administration instructions?

How to Take Eltrombopag Tablets

Take eltrombopag on an empty stomach or with a low-calcium meal (≤50 mg calcium), and separate it from polyvalent cations by at least 2 hours before or 4 hours after taking antacids, calcium-rich foods, dairy products, or mineral supplements 1.

Timing and Food Restrictions

The most critical aspect of eltrombopag administration is avoiding interference with absorption:

• Take without food OR with a low-calcium meal only (≤50 mg calcium)

• Avoid all dairy products, calcium-fortified foods, and mineral supplements within the dosing window

• Wait at least 2 hours before taking eltrombopag after consuming:

  • Antacids
  • Calcium-rich foods or supplements
  • Iron supplements
  • Multivitamins containing minerals

• Wait at least 4 hours after taking eltrombopag before consuming these products 1

This strict separation is essential because polyvalent cations (calcium, iron, magnesium, aluminum, zinc) form chelation complexes with eltrombopag, dramatically reducing its bioavailability and rendering treatment ineffective.

Dosing by Indication

For Immune Thrombocytopenia (ITP)

Starting dose: 50 mg once daily for most adult patients 1. However, specific populations require dose adjustments:

• East/Southeast Asian ancestry patients: Start at 25 mg once daily 1
• Hepatic impairment: Reduced starting dose required 1
• Pediatric patients (6-17 years):
  • Age 12-17 years: 50 mg once daily
  • Age 6-11 years weighing ≥27 kg: 50 mg once daily (25 mg for East Asian patients)
  • Age 6-11 years weighing <27 kg: 25 mg once daily (12.5 mg for East Asian patients)
  • Age 1-5 years: 25 mg once daily 1, 2

Target platelet count: ≥50 × 10⁹/L 1. The ASH guidelines support using eltrombopag as a second-line agent for ITP lasting ≥3 months in patients who are corticosteroid-dependent or unresponsive 3.

Maximum dose: 75 mg per day (do not exceed) 1

For Chronic Hepatitis C-Associated Thrombocytopenia

Starting dose: 25 mg once daily for all patients 1

Maximum dose: 100 mg per day 1

For Severe Aplastic Anemia

Starting dose: 50 mg once daily 1

Maximum dose: 150 mg per day 1

Dose Titration Strategy

Based on real-world evidence, the 50 mg starting dose achieves significantly higher initial response rates (85.9%) compared to 25 mg (74.1%) or 75 mg (60.0%) 4. This supports starting at 50 mg for most patients rather than lower doses.

Adjust dose every 2 weeks based on platelet response:

• If platelets remain <50 × 10⁹/L after 2 weeks, increase by 25 mg increments
• If platelets exceed 150-200 × 10⁹/L, reduce dose by 25 mg
• If platelets exceed 400 × 10⁹/L, hold dose until <150 × 10⁹/L, then resume at reduced dose

Median time to response: 7-14 days 4, 2, with over 80% of patients showing platelet increases by day 15 5.

Important Clinical Considerations

Common Pitfalls to Avoid

1. Food interactions: The most common reason for treatment failure is inadequate separation from calcium and other minerals. Patients must understand this is non-negotiable.

2. Premature dose escalation: Wait the full 2 weeks before increasing dose, as response may be delayed 1

3. Abrupt discontinuation: Thrombocytopenia worsens upon stopping eltrombopag 5. Taper gradually when discontinuing.

Monitoring Requirements

• Platelet counts: Weekly initially, then monthly once stable
• Liver function tests: Monitor regularly, as 7.7-13% of patients develop transaminase elevations 5, 4
• Bleeding assessment: Document bleeding scores at baseline and during treatment

Safety Concerns

Thrombotic risk exists, particularly when platelet counts exceed target ranges 5, 6. One case report documented cerebral venous sinus thrombosis following eltrombopag use 6. Maintain platelets at goal (50-150 × 10⁹/L) rather than maximizing counts.

Bone marrow reticulin: Increased reticulin deposition reported with prolonged use 5

Hepatotoxicity: Liver function abnormalities occur in up to 13% of patients 5. Two patients in clinical trials discontinued due to elevated ALT 2.

Duration of Therapy

Eltrombopag requires continuous administration to maintain platelet response 5. Real-world data shows sustained responses up to 1.5-4 years with ongoing treatment 5.

In pediatric patients, dose de-escalation is feasible in 94% of cases, with 15% achieving complete discontinuation 7. A proposed tapering schedule involves 25% dose reduction every 4 weeks in responding patients 7.